IGF-I assays: current assay methodologies and their limitations.
about
Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular diseaseMotivations and methods for analyzing pulsatile hormone secretionTargeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference.Monitoring of acromegaly: what should be performed when GH and IGF-1 levels are discrepant?Insulin-like growth factors in the peripheral nervous system.Reference Values for IGF-I Serum Concentrations: Comparison of Six ImmunoassaysMultiple facets in the control of acromegaly.In active acromegaly, IGF1 bioactivity is related to soluble Klotho levels and quality of life.Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection.Diagnosis of acromegaly: state of the art.Association between Serum IGF-I levels and Postoperative Delirium in Elderly Subjects Undergoing Elective Knee Arthroplasty.Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance.Biochemical investigations in diagnosis and follow up of acromegaly.Reference ranges for an automated chemiluminescent assay for serum insulin-like growth factor I (IGF-I) in a large population of healthy adults from Buenos Aires.Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry.Therapeutic options in the management of acromegaly: focus on lanreotide Autogel.Characteristics and reference ranges of Insulin-Like Growth Factor-I measured with a commercially available immunoassay in 724 healthy adult Caucasians.Direct determination of the binding sites of cisplatin on insulin-like growth factor-1 by top-down mass spectrometry.Advances in human chorionic gonadotropin detection technologies: a review.Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols Advantage IGF-I in a growth hormone treated population.
P2860
Q28075372-3AEF2FE4-4B29-4D6A-BD50-F97E902C1CACQ30437731-3AFED38D-F146-4AF3-8C12-51507C95903BQ35053898-332CD754-9ACC-4FA1-B428-CD4F99B01F47Q36415876-1EFD6267-316E-4832-B367-B4667A22D283Q36845980-AFC64245-CA7C-4548-BC90-66F1E25F59ABQ37034921-B739A2FD-41B0-439F-A516-8892871CB7EFQ37318566-854516D4-5A8E-466C-B11B-FF5FD0F344F9Q37531066-D8FC2338-78D2-45AF-A2FA-549A667E2D42Q37726834-7928F19C-BDBC-4D1D-82F0-868477BEDA1EQ38128225-6397F859-30F2-482F-9B05-A1AF3FC01280Q38131055-FE013AA4-F6A2-4BC7-9FF5-440D1D91EE8CQ38266562-34E8E93D-42B9-4B43-8004-131024798A47Q38990078-63692EAB-7F02-410E-BAD3-633849ED48F8Q39123579-1C15A364-A5C8-4687-B5AA-A8FDF9F7B750Q41295170-3D934F59-D1C6-41DC-AE77-E4F47F979415Q42324675-03019E95-5209-401A-85D3-7F6B314A5566Q43078115-4669E347-FA1A-4CA4-B6B1-5646FB2EB026Q43292683-A7734802-CC90-406A-942F-3C2059EA8388Q43961118-48803DC0-4B2A-4E2A-B8AB-4246EA1D6972Q47423756-787B1F2D-1FEB-4DD2-A0AD-D41B91C708BCQ51861103-91FDD3E2-E45E-46B0-B019-4A54CC2F5583
P2860
IGF-I assays: current assay methodologies and their limitations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
IGF-I assays: current assay methodologies and their limitations.
@en
type
label
IGF-I assays: current assay methodologies and their limitations.
@en
prefLabel
IGF-I assays: current assay methodologies and their limitations.
@en
P1433
P1476
IGF-I assays: current assay methodologies and their limitations.
@en
P2093
David R Clemmons
P2888
P304
P356
10.1007/S11102-007-0032-Z
P577
2007-01-01T00:00:00Z